Abstract Library

Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.

Participants of the ENETS Conference in 2022 can now access the abstract booklet, e-posters and videos, the poster carousel, and more via My ENETS.

ENETS Abstract Search

#1480 Systemic Treatment Sequences across Europe for Patients (pts) with Advanced Non-functional (NF) Well-Differentiated Pancreatic Neuroendocrine Tumours (WD pNETs)

Introduction: Different systemic therapies (ST) are available for pts with advanced WD pNETs; however, the best treatment modalities and optimal sequencing are currently unknown.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Custodio A

Authors: Custodio A, Van Adrichem R, Brizzi M, Heetfeld M, Jimenez-Fonseca P,

Keywords: pNET, treatment sequences,

#979 Characteristics and Treatments of Patients with G3 Gastroenteropancreatic Neuroendocrine Tumors (G3-NET) and Neuroendocrine Carcinoma (NEC): A European Multicenter Retrospective Study

Introduction: Data on G3-NET and NEC are limited. No standard therapy following platinum-etoposide failure is established and first-line therapy in G3-NET is not codified.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author:

Authors: Heetfeld M, Rinke A, Borbath I, Crespo G, Olsen I,

Keywords: gastrointestinal cancer, neuroendocrine carcinoma, grade 3 NET, Ki-67, chemotherapy,

#956 Treatment Practices in European Centers with Interest in Neuroendocrine Carcinomas and High Grade (G3) Neuroendocrine Tumors

Introduction: Aggressive neuroendocrine neoplasms (NEN) encompass both poorly differentiated carcinomas (NEC) and high grade neuroendocrine tumors (G3-NET) with a Ki-67 index >20%; WHO 2010.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author: olsen i

Authors: Olsen I, Borbath I, Heetfeld M, Walter T, Barriuso J,

Keywords: neuroendocrine carcinoma, Ki-67, immunohistochemistry, treatment,

#568 Efficacy of Everolimus and Tolerability with Long-Term Use

Introduction: Predictors of response to Everolimus in neuroendocrine tumors and long-term safety data are lacking.

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: Heetfeld M, Tischer E, Denecke T, Perez Fernandez C, Wiedenmann B,

Keywords: everolimus, prior therapies, pneumonitis ,

Abstract Submissions in 2023

Abstract submissions for 2023 will open in September 2022!

 

The 20th Annual ENETS Conference in 2023 will provide the principal platform for NET researchers around the world to present their latest findings. ENETS will select the best abstracts submitted in both clinical and basic science and present these in sessions within the framework of its scientific programme.

 

Participants of the ENETS Conferences in 2022 can now access the abstract booklet, e-posters and videos, the poster carousel, and more via My ENETS.

Membership matters

Multidisciplinary is our credo. We welcome all NET-related disciplines and professionals! Learn more about the benefits of becoming an ENETS member.